Dow Down1.29% Nasdaq Down3.25%

Bristol-Myers Squibb Company (BMY)

-NYSE
59.63 Down 0.07(0.12%) Feb 5, 4:01PM EST
|After Hours : 59.62 Down 0.01 (0.02%) Feb 5, 5:30PM EST
ProfileGet Profile for:
Bristol-Myers Squibb Company
345 Park Avenue
New York, NY 10154
United States - Map
Phone: 212-546-4000
Website: http://www.bms.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Major
Full Time Employees:N/A

Business Summary 

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The company’s products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; and Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. Its products also comprise Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia for use in treating patients with moderately to severely active rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. In addition, it is developing Opdivo, a human monoclonal antibody, which is in Phase III trials for non-small cell lung cancer, renal cell cancer, and melanoma; Beclabuvir, a non-nucleoside NS5B inhibitor that is in Phase III development for the treatment of HCV; Elotuzumab, a humanized monoclonal antibody, which is in Phase III trials for the treatment of multiple myeloma; and BMS-663068, an investigational compound that is being studied in HIV-1. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Bristol-Myers Squibb Company

Corporate Governance 
Bristol-Myers Squibb Company’s ISS Governance QuickScore as of Feb 1, 2016 is 9. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 5; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Giovanni Caforio M.D., 51
Chief Exec. Officer and Director
3.24M1.45M
Mr. Charles A. Bancroft , 56
Chief Financial Officer and Exec. VP
2.76M1.10M
Dr. Francis M. Cuss MB BChir, FRCP, 61
Chief Scientific Officer, Exec. VP and Member of Science & Technology Committee
2.76M2.65M
Ms. Sandra Leung , 55
Exec. VP and Gen. Counsel
2.38M392.00K
Mr. Paul Von Autenried , 54
Chief Information Officer and Sr. VP of Enterprise Services
N/AN/A
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders